BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ago Y, Asano S, Hashimoto H, Waschek JA. Probing the VIPR2 Microduplication Linkage to Schizophrenia in Animal and Cellular Models. Front Neurosci 2021;15:717490. [PMID: 34366784 DOI: 10.3389/fnins.2021.717490] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Sakamoto K, Asano S, Ago Y, Hirokawa T. AlphaFold version 2.0 elucidates the binding mechanism between VIPR2 and KS-133, and reveals an S–S bond (Cys25−Cys192) formation of functional significance for VIPR2. Biochemical and Biophysical Research Communications 2022;636:10-16. [DOI: 10.1016/j.bbrc.2022.10.071] [Reference Citation Analysis]
2 Lu J, Piper SJ, Zhao P, Miller LJ, Wootten D, Sexton PM. Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors. IJMS 2022;23:8069. [DOI: 10.3390/ijms23158069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chen CH, Cheng MC, Hu TM, Ping LY, Kushima I, Aleksic B. Identification of rare mutations of the vasoactive intestinal peptide receptor 2 gene in schizophrenia. Psychiatr Genet 2022:YPG. [PMID: 35353798 DOI: 10.1097/YPG.0000000000000313] [Reference Citation Analysis]
4 Sakamoto K, Chen L, Miyaoka T, Yamada M, Masutani T, Ishimoto K, Hino N, Nakagawa S, Asano S, Ago Y. Generation of KS-133 as a Novel Bicyclic Peptide with a Potent and Selective VIPR2 Antagonist Activity that Counteracts Cognitive Decline in a Mouse Model of Psychiatric Disorders. Front Pharmacol 2021;12:751587. [PMID: 34819858 DOI: 10.3389/fphar.2021.751587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]